PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy

Paul M. Schroder, Mithun Khattar, Caitlin E. Baum, Yoshihiro Miyahara, Wenhao Chen, Rohit Vyas, Shravan Muralidharan, Beata Mierzejewska, Stanislaw M. Stepkowski

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Aims/hypothesis: T cells play a major role in the pathogenesis of type 1 diabetes, and there is great interest in developing curative immunotherapies targeting these cells. In this study, a monoclonal antibody (mAb) targeting the T cell receptor β-chain (TCRβ) was investigated for its ability to prevent and reverse disease in mouse models of diabetes. Methods: RIP-OVAhi (C57BL/6-Tg(Ins2-OVA)59Wehi/WehiJ) mice adoptively transferred with ovalbumin-specific T cells (an induced model of diabetes) and NOD mice (a spontaneous model of diabetes) were used to test anti-TCRβ mAb therapy as a means of preventing and reversing type 1 diabetes. Results: A single dose of anti-TCRβ completely prevented disease in RIP-OVAhi mice without inducing the release of inflammatory cytokines. Transient anti-TCRβ therapy prevented diabetes in 90% of NOD mice and reversed the disease after its onset in 73% of NOD mice. Long after the remission of type 1 diabetes, the anti-TCRβ treated mice were able to reject BALB/c skin allografts with normal kinetics while maintaining normoglycaemia. Treatment did not cause significant reductions in lymphocyte numbers in the spleen or pancreatic lymph nodes, but did result in a decreased percentage of chemokine receptor 9 (CCR9) positive, CD8+ T cells. Notably, anti-TCRβ therapy increased the expression of programmed death 1 (PD-1) on the surface of the T cells; PD-1 expression is important for maintaining anti-TCRβ-induced self-tolerance, as type 1 diabetes recurs in mice following a blockade of PD-1 signalling. Conclusions/interpretation: Anti-TCRβ mAb is a safe and effective immunotherapy that results in reduced numbers of CCR9+ T cells, an increased expression of PD-1 on T cells and the restoration of self-tolerance in NOD mice.

Original languageEnglish (US)
Pages (from-to)1309-1318
Number of pages10
JournalDiabetologia
Volume58
Issue number6
DOIs
StatePublished - Jun 1 2015

Keywords

  • Antibody
  • Autoimmunity
  • Immunotherapy
  • NOD mice
  • PD-1
  • Self-tolerance
  • T cell receptor
  • T cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy'. Together they form a unique fingerprint.

Cite this